Journal

What Happens After You Stop Tirzepatide?

Use SURMOUNT-4 and avoid individualized advice

The trial that changes the arithmetic

Most GLP-1 coverage focuses on how much weight comes off. SURMOUNT-4 asked the more consequential question: what happens when you stop.

The design was a randomised withdrawal. All 670 participants took tirzepatide openly for 36 weeks, then were randomised either to continue or to switch to placebo for a further 52 weeks. Over that period, the continuing group lost a further 5.5% of body weight. The withdrawn group regained 14.0%.

What that means clinically

It is consistent with how obesity is understood as a chronic condition: the treatment manages it while present, and its effect does not persist after withdrawal. This is unremarkable for chronic disease medicine — nobody expects blood pressure to stay controlled after stopping an antihypertensive — but it collides with how weight-loss treatment is usually marketed, as a course with an endpoint.

One important caveat: everyone in SURMOUNT-4 completed a 36-week lead-in, so both arms are a population that tolerated and responded to the drug. The trial also tested abrupt withdrawal to placebo. It says nothing about tapering, or about structured maintenance at a reduced dose, because neither was studied.

What it means financially

This is the part almost no pricing page mentions. If maintaining the result requires maintaining the medication, the relevant figure is not the first-month rate and not even the annual cost. It is the indefinite monthly cost.

A patient choosing a provider on a discounted introductory month is optimising the wrong variable by a large margin. The questions that matter are what the price is at a maintenance dose, whether it is fixed or escalates, and what happens to a prepaid balance if circumstances change.

It also reframes prepaid plans. A twelve-month prepayment lowers the monthly figure and raises the amount at risk. For a treatment likely to continue indefinitely, that trade may be reasonable — but it should be made deliberately, not because the annual rate was the number displayed largest.

Questions for your clinician

1. What is the maintenance plan, and for how long?
2. If I need to stop, is there a tapering approach, and what is known about it?
3. What should I expect if I stop, and what would we do about it?
4. How does the answer change my choice of programme and billing term?

What the regain figure does and does not describe

Fourteen per cent regain over 52 weeks is a group mean in people who had already completed a 36-week lead-in. Individual trajectories varied, and some participants held more of their loss than others.

What the trial cannot tell you is why. Whether regain reflects appetite returning to baseline, metabolic adaptation, behavioural drift, or some combination is not settled by a weight measurement.

The tapering question, and why it is unanswered

SURMOUNT-4 randomised to continuation or to placebo — an abrupt switch. It did not test dose reduction, gradual withdrawal, or intermittent dosing.

Every provider marketing microdosing as a maintenance strategy is therefore proposing something the withdrawal literature has not evaluated. It may work. Nobody has shown it does, and the trial most often cited in support of it tested a different thing.

What this does to the economics of a purchase decision

If treatment holds its result only while present, three commonly-marketed features lose most of their value.

Introductory pricing applies to one month of an indefinite course. Eleven programmes in our dataset advertise a first-month rate; we exclude all of them from every ranking.

Annual totals understate the commitment. The relevant figure is the indefinite monthly cost at a maintenance dose.

Prepayment discounts trade flexibility for a lower monthly figure, which is reasonable for someone already established on treatment and a poor bet for someone who has not yet discovered whether they tolerate it.

Questions worth asking before you start, not after

1. What is the maintenance plan, and for how long do you expect me to be on this?
2. If I need to stop, how would you manage it, and what does the evidence support?
3. What should I expect if I stop, and what would we do about it?
4. Does that change which programme or billing term makes sense for me?

Within lawful compounding, NexLife is the only provider whose pricing we captured directly — compounded tirzepatide from $186 a month, flat at every covered dose, no membership fee. See its plans.

Questions readers actually ask